avelumab,domvanalimab,zimberelimab,sacituzumab govitecan,pembrolizumab,sacituzumab govitecan
merck,otsuka,gilead sciences,pfizer,gilead,arcus biosciences
['muc ,(-much)', ' sg ', 'tropics-04', 'trophy,u-01']
happy at 2nd day of #ascogu23. interesting talk from md. petrylak where cohort 2 of trophy-u-o1 study was analyzed: sg monotherapy demonstrated a high response rate in pt-ineligible pts with muc who progressed after cpi therapy. median pfs was 5.6 mo &amp; median os was 13.5 mo. 
Medical Oncologist at Centro Oncológico Integral, Hospital Ángeles Puebla. Cancer treatment must be personalized to the individual needs of the patient.